Seminarium Fizyki Biomedycznej

While DNA damage is a fundamental biological process, the ability to detect it with precision is a game-changer for modern medicine. From evaluating the efficacy of oncology treatments to monitoring environmental toxicity, the clarity of our "genetic vision" directly impacts clinical outcomes.This seminar introduces STRIDE® (Sensitive Recognition of Individual DNA Ends), a breakthrough technology designed to bridge the gap between basic research and clinical application. Unlike traditional methods that rely on indirect markers, STRIDE provides the most proximal readout of DNA integrity by directly labeling the free ends of DNA breaks in situ. We will move beyond theory to discuss the practical benefits of STRIDE assays, including their role in drug development (particularly for DDR inhibitors), personalized medicine, and the assessment of DNA repair capacity in patient-derived samples.By providing a high-resolution, quantitative map of genomic damage, STRIDE allows researchers and clinicians to move from "educated guesses" to objective data. We will explore how this sensitivity is essential for developing the next generation of targeted therapies and ensuring they are safe and effective for patients.We will also share the story of intoDNA’s origins, tracing how a breakthrough in academic curiosity at the Jagiellonian University evolved into a specialized biotech venture. Today, intoDNA partners with global pharmaceutical leaders to accelerate the development of life-saving therapeutics, proving that deep-tech innovation can successfully transition from the university bench to the global clinical stage.